馃敟 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 馃敟
The ESMO Presidential Symposium is always one of the highlights of the congress, and today鈥檚 session promises some truly extraordinary science!
If I had to pick ONE study with the greatest potential to change clinical practice at ESMO 2026, my choice would be DeLLphi-305.
For decades, SCLC has been one of the most challenging diseases in oncology, with far too little progress and far too few therapeutic breakthroughs.
Could DeLLphi-305 finally represent the major leap forward we have been waiting for? We already know that adding tarlatamab to durvalumab as first-line maintenance significantly improves OS compared with durvalumab alone. But today, we will finally see the numbers. And I am genuinely excited to discover just how transformative this benefit might be! My personal bet for the biggest breakthrough of #ESMO26? DeLLphi-305. @StephenVLiu @sands_jacob
Of course, the magnitude of survival benefit, safety and clinical applicability will ultimately determine its impact. But the potential is enormous. Don鈥檛 miss today鈥檚 Presidential Symposium!
Madrid | 馃暉 16:30 CEST Alicante auditorium
#ESMO26 #ESMOAmbassador #SCLC #LungCancer #Immunotherapy #Oncology #PracticeChanging
175 views 路 6 likes 路 2 reposts 路 1 reply
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Molly Li@mollylisc
@Alfdoc2 With BiTe in the first line, SCLC will no longer be an incurable disease. A good portion of patients will have long term control.
Source: Alfredo Addeo MD 路 x.com